THE FUTURE OF HEALTHCARE

whitePaper | June 3, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible.

whitePaper | December 7, 2022

The target market for conducting global clinical trials has changed significantly, moving beyond pharmaceutical early adopters to the mainstream marketplace.

whitePaper | January 9, 2020

Radiation therapy is one of the most common treatments used to fight cancer in the U.S., with more than half of cancer patients receiving it either alone or in combination with other medical interventions.1 With the traditional approach to radiation therapy, the dose and schedule is tailored to the tumor type, location, and stage of growth, but only infrequently updated in light of changes after treatment starts. Experts in adaptive therapy are looking to deliver a more personalized treatment strategy guided by the individual patient’s needs.

whitePaper | July 1, 2022

Too often health is something we try not to think about. We avoid talking about it. We put it off for another day, a better time. Then, something unexpected happens: an illness, an unfortunate incident, or even, as we’ve seen these last two and a half years, a pandemic.

whitePaper | September 26, 2022

As hospitals and private health offices nationwide slowly begin to emerge from the COVID-induced challenges posed over the last two years, there is a new understanding of, and necessity for, adaptable medical technology and practices.

whitePaper | November 19, 2022

Now, more than ever, sponsors and CROs need to prioritize including patient engagement in their study builds from the ground-up. This involves defining processes to remove barriers for access.